Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2004 3
2005 1
2006 1
2009 3
2010 4
2011 5
2012 12
2013 10
2014 11
2015 11
2016 15
2017 11
2018 11
2019 14
2020 9
2021 9
2022 10
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Among authors: stephans kl. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Videtic GM, et al. Among authors: stephans kl. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1. Int J Radiat Oncol Biol Phys. 2019. PMID: 30513377 Free PMC article. Clinical Trial.
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
Ganguly S, Lone Z, Muskara A, Imamura J, Hardaway A, Patel M, Berk M, Smile TD, Davicioni E, Stephans KL, Ciezki J, Weight CJ, Gupta S, Reddy CA, Tendulkar RD, Chakraborty AA, Klein EA, Sharifi N, Mian OY. Ganguly S, et al. Among authors: stephans kl. J Clin Invest. 2023 Nov 15;133(22):e165718. doi: 10.1172/JCI165718. J Clin Invest. 2023. PMID: 37966114 Free PMC article.
Management of Oligometastatic Prostate Cancer.
Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Broughman JR, et al. Among authors: stephans kl. Appl Radiat Oncol. 2020 Sep;9(3):6-10. Epub 2020 Sep 9. Appl Radiat Oncol. 2020. PMID: 33134438 Free PMC article. No abstract available.
Intriguing, but Not the Right Setting.
Stephans KL, Kotecha R. Stephans KL, et al. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):495. doi: 10.1016/j.ijrobp.2017.01.215. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581388 No abstract available.
121 results